Despite these potential benefits, there is currently no safe way to microdose Wegovy as the practice hasnt been clinically studied
The rates are remarkably similar across all three, despite their different mechanisms: Semaglutide: Nausea approximately 18%, diarrhea approximately 12%, vomiting approximately 8% Tirzepatide: Nausea 17-22% (dose dependent), diarrhea 13-16%, vomiting 6-10% Retatrutide: Nausea 16-25% (dose dependent), diarrhea 15-22%, vomiting 8-13% The pattern holds consistently
A good candidate for semaglutide often has a pattern I recognize during consultation: consistent effort, limited results, and a body that seems to be working against them
Avoid freezing, and protect your medication from heat, sunlight, and high temperatures in cars
It is also suitable for researchers who want to test semaglutide before committing to a larger purchase